Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-04: evorpacept with pembrolizumab and chemotherapy in advanced head and neck squamous cell carcinoma
NL-OMON59770Phase 2Completed
- Sponsor
- ALX Oncology
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of evorpacept, sponsored by ALX Oncology. Started Mar 2022; status: completed.
02
Drugs
evorpacept
Beyond the preview
Go deeper on NL-OMON59770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59770.